Last edition
News about
Daiichi Sankyo has dosed the first patient in a phase 1 clinical trial of DS3610, its investigational STING agonist Antibody Drug Conjugate (ADC), marking a key step in advancing novel immunotherapy approaches for patients with advanced solid tumours.
Granules Life Sciences Secures First US FDA Approval for Metformin HCl Tablets
Granules Life Sciences Private Limited, a wholly owned subsidiary of Granules India Limited, has obtained its first approval from the US Food and Drug Administration (US FDA) for Metformin HCl tablets.
JB Pharma Q2 FY26 Net Profit Rises 19 Percent to INR 208 Crore
JB Chemicals & Pharmaceuticals reported a net profit of INR 208 crore for the quarter ended September 30, 2025, marking a 19 percent year-on-year increase from INR 175 crore in the same period last year.
Lupin Manufacturing Solutions Commissions Dedicated Oncology Block at Vizag Facility
Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of global pharma major Lupin, has commissioned a dedicated oncology manufacturing block at its Vizag facility in India.
Novartis Opens New Radioligand Therapy Plant in California under USD 23 Billion US Expansion Plan
Novartis has inaugurated its third US-based radioligand therapy (RLT) manufacturing facility in Carlsbad, California, expanding its production network to meet growing demand and maintain a 99.9 percent on-time delivery rate for patients across the western United States, Alaska, and Hawaii.
Biocon Posts Robust Q2FY26 Results as Biosimilars and Generics Drive Double-Digit Growth
Biocon reported a robust financial performance for the second quarter of FY26, with total revenue rising 21 percent year-on-year (YoY) to INR 4,389 crore, compared to INR 3,623 crore in Q2 FY25.
Indian Pharma Firms Selected to Supply Key Generic Drugs in China
Several Indian pharmaceutical companies—including Cipla Ltd, Hetero Labs Limited, Natco Pharma Limited, and Annora Pharma Private Limited—have won bids to supply generic medicines to public hospitals in China under the country’s volume-based procurement (VBP) programme.
Primrose Bio Launches Next-Gen RNA Polymerase for Self-Amplifying mRNA
Primrose Bio has introduced Prima RNApols ExTend Cap AU, an advanced RNA polymerase designed to enhance capping efficiency and reduce double-stranded RNA formation in the production of self-amplifying mRNA, improving yield and quality in mRNA manufacturing.
GENFIT and EVerZom Partner to Advance Exosome-based Regenerative Technology in ACLF
Under the collaboration, GENFIT and EVerZom will combine expertise to advance EViv, an exosome-based regenerative therapy for ACLF, with GENFIT leading preclinical evaluation and EVerZom providing its bioproduction platform. GENFIT also holds an exclusive option to licence the programme following successful proof-of-concept results.
Sun Pharmaceutical’s partner Philogen, a Swiss-Italian biotechnology company, has provided an update on the Phase III FIBROSARC trial evaluating Fibromun (L19TNF) in combination with doxorubicin versus doxorubicin alone as first-line treatment for patients with advanced or metastatic Soft Tissue Sarcoma (STS).
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy